These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31843355)

  • 1. [Immune check point inhibitor-associated renal toxicity].
    Izzedine H; Gueutin V
    Nephrol Ther; 2020 Feb; 16(1):19-26. PubMed ID: 31843355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Renal toxicities of targeted therapies in oncology].
    Izzedine H
    Nephrol Ther; 2020 Feb; 16(1):1-8. PubMed ID: 31818703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal Toxicity.
    Abdelrahim M; Abudayyeh A
    Adv Exp Med Biol; 2020; 1244():287-293. PubMed ID: 32301023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?
    Perazella MA; Shirali AC
    Kidney Int; 2020 Jan; 97(1):62-74. PubMed ID: 31685311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal immune-related adverse events of immune checkpoint inhibitor.
    Hu R; Chen M; Xu Y; Wang M; Zheng K; Li X
    Asia Pac J Clin Oncol; 2020 Dec; 16(6):305-311. PubMed ID: 32573099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer.
    Jagieła J; Bartnicki P; Rysz J
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33924827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives.
    Dougan M
    Curr Gastroenterol Rep; 2020 Mar; 22(4):15. PubMed ID: 32185493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor-induced renal immune-related adverse events.
    Zheng K; Qiu W; Wang H; Si X; Zhang X; Zhang L; Li X
    Thorac Cancer; 2020 Jun; 11(6):1746-1751. PubMed ID: 32232975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal Toxicity.
    Abdelrahim M; Abudayyeh A
    Adv Exp Med Biol; 2021; 1342():389-397. PubMed ID: 34972976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review.
    Wanchoo R; Karam S; Uppal NN; Barta VS; Deray G; Devoe C; Launay-Vacher V; Jhaveri KD;
    Am J Nephrol; 2017; 45(2):160-169. PubMed ID: 28076863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical Diagnosis and Treatment Recommendation of Immune-related Adverse Renal Events Related to Immune Checkpoint Inhibitor].
    Qiu W; Zheng K; Wang H; Si X; Zhang X; Li X; Zhang L
    Zhongguo Fei Ai Za Zhi; 2019 Oct; 22(10):645-648. PubMed ID: 31650947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kidney Complications of Immune Checkpoint Inhibitors: A Review.
    Shingarev R; Glezerman IG
    Am J Kidney Dis; 2019 Oct; 74(4):529-537. PubMed ID: 31303350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors.
    Ibraheim H; Perucha E; Powell N
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii17-vii28. PubMed ID: 31816081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Predictive Biomarkers of Immune-related Adverse Events Induced by Checkpoint Inhibitors in Malignancies].
    Tang H; Guan M; Sun Z; Bai CM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2020 Dec; 42(6):825-830. PubMed ID: 33423733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Immunotherapy-Related Toxicities in Patients Treated With Immune Checkpoint Inhibitor Therapy.
    Reid PD; Cifu AS; Bass AR
    JAMA; 2021 Feb; 325(5):482-483. PubMed ID: 33528524
    [No Abstract]   [Full Text] [Related]  

  • 16. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update.
    Nagai H; Muto M
    Int J Clin Oncol; 2018 Jun; 23(3):410-420. PubMed ID: 29516216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular, Renal and Pulmonary Toxicity of Immune Checkpoint Inhibitors in Cancer: What the GP Should Know.
    Smekens L; Genoud V; Usdin N; Ben Aïssa A
    Praxis (Bern 1994); 2023; 112(3):160-171. PubMed ID: 36855889
    [No Abstract]   [Full Text] [Related]  

  • 18. Delayed cytokine release syndrome after neoadjuvant nivolumab: a case report and literature review.
    Ciner AT; Hochster HS; August DA; Carpizo DR; Spencer KR
    Immunotherapy; 2021 Sep; 13(13):1071-1078. PubMed ID: 34287029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
    Puzanov I; Diab A; Abdallah K; Bingham CO; Brogdon C; Dadu R; Hamad L; Kim S; Lacouture ME; LeBoeuf NR; Lenihan D; Onofrei C; Shannon V; Sharma R; Silk AW; Skondra D; Suarez-Almazor ME; Wang Y; Wiley K; Kaufman HL; Ernstoff MS;
    J Immunother Cancer; 2017 Nov; 5(1):95. PubMed ID: 29162153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrolyte and Acid-Base Disorders Associated with Cancer Immunotherapy.
    Uppal NN; Workeneh BT; Rondon-Berrios H; Jhaveri KD
    Clin J Am Soc Nephrol; 2022 Jun; 17(6):922-933. PubMed ID: 35063968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.